home / stock / hook / hook quote
Last: | $ |
---|---|
Change Percent: | -3.60% |
Open: | $12.50 |
Close: | $12.04 |
High: | $12.6839 |
Low: | $12.00 |
Volume: | 80,315 |
Last Trade Date Time: | 02/12/2020 04:41:40 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $12.50 | $12.04 | $12.6839 | $12.00 | 80,315 | 02-12-2020 |
$ | $12.71 | $12.49 | $12.8159 | $12.40 | 44,392 | 02-11-2020 |
$ | $13.09 | $12.72 | $13.33 | $12.70 | 35,152 | 02-10-2020 |
$ | $12.57 | $13.13 | $13.30 | $12.57 | 52,249 | 02-07-2020 |
$ | $13.73 | $12.56 | $14.14 | $12.50 | 65,671 | 02-06-2020 |
$ | $13.06 | $13.69 | $13.95 | $12.9221 | 54,415 | 02-05-2020 |
$ | $12.79 | $12.95 | $13.02 | $12.61 | 44,264 | 02-04-2020 |
$ | $12.16 | $12.59 | $12.99 | $12.01 | 51,188 | 02-03-2020 |
$ | $12.66 | $12.00 | $12.98 | $11.99 | 106,856 | 01-31-2020 |
$ | $12.83 | $12.66 | $13.4431 | $12.55 | 38,672 | 01-30-2020 |
$ | $12.41 | $12.75 | $13.2858 | $12.41 | 68,435 | 01-29-2020 |
$ | $13.15 | $12.41 | $13.9802 | $12.26 | 70,814 | 01-28-2020 |
$ | $12.21 | $13.00 | $13.82 | $12.17 | 141,310 | 01-27-2020 |
$ | $14.01 | $12.06 | $14.3662 | $12.005 | 140,232 | 01-24-2020 |
$ | $12.23 | $13.80 | $14.00 | $12.05 | 222,240 | 01-23-2020 |
$ | $12.14 | $12.05 | $12.4967 | $11.91 | 123,646 | 01-22-2020 |
$ | $12.40 | $12.20 | $12.60 | $11.83 | 320,214 | 01-21-2020 |
$ | $11.35 | $11.19 | $11.37 | $11.08 | 31,501 | 01-20-2020 |
$ | $11.35 | $11.19 | $11.37 | $11.08 | 31,104 | 01-17-2020 |
$ | $11.2896 | $11.25 | $11.58 | $11.07 | 49,334 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collabora...
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrati...
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20 Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc....